HRI Statement on retraction of Frass et al. 2020 study which found benefits of ‘add-on’ homeopathy for cancer patients undergoing conventional cancer treatment
4 декември 2025On 24 November, a clinical trial by Frass et al. 20201 assessing homeopathy provided in addition to usual oncology care in non-small-cell lung carcinoma patients, was retracted by the Editor of the journal. This study, using the gold-standard double-blind placebo-controlled trial design, found that patients receiving additional homeopathic treatment had improved quality of life and increased survival time, compared to the placebo group. More | DE










